Loading organizations...
NOTA Laboratories develops innovative nitric oxide (NO) delivery platforms augmenting the body's natural NO production. Their core technology focuses on proprietary systems providing sustained, controlled release of NO, mimicking endogenous physiological processes. The company aims to make these advanced NO delivery solutions accessible for both hospital and in-home use, addressing diverse medical conditions.
Founded in 2014, NOTA Laboratories emerged as a spin-out from the University of Michigan. Dr. Mark Meyerhoff, Mark A. Zacharek, and Marc B. Hershenson were instrumental in its inception. Dr. Meyerhoff’s personal experience with chronic sinusitis provided the key insight into novel nitric oxide applications, driving the company's foundational therapeutic development.
NOTA Laboratories designs products for patients with conditions benefiting from nitric oxide therapy, including respiratory and systemic health challenges. The company envisions a future where accessible and effective nitric oxide delivery technologies prevent and treat many chronic and life-threatening diseases. They are dedicated to advancing their science to continuously improve patient outcomes.
NOTA Labs has raised $4.0M across 1 funding round.
NOTA Labs has raised $4.0M in total across 1 funding round.
NOTA Labs has raised $4.0M across 1 funding round. Most recently, it raised $4.0M Series U in April 2022.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Apr 1, 2022 | $4M Series U | — | Pegasus Tech Ventures | Announced |
NOTA Labs has raised $4.0M in total across 1 funding round.
NOTA Labs's investors include Pegasus Tech Ventures.
NOTA Laboratories is a healthcare technology company founded in 2014 that develops innovative nitric oxide (NO) delivery platform technologies to treat and prevent debilitating conditions.[1][2][3][4] These platforms harness NO's natural properties as an antimicrobial, antiviral, anti-inflammatory, anti-thrombotic, and vasodilatory agent, targeting respiratory infections, persistent pulmonary hypertension in newborns (PPHN), chronic obstructive pulmonary disease (COPD), catheter-related bloodstream infections (CRBSI), systemic inflammatory response syndrome (SIRS), and complications from open heart surgery.[1][4] The company serves patients with life-threatening illnesses, including those affected by COVID-19, seasonal flu, and common cold, through affordable systems like the electrochemical NOGEN and UV-LED-based LANOR, backed by U.S. National Institutes of Health funding via the small business innovation program.[1][2]
NOTA Laboratories was established in 2014 with a focus on NO delivery platforms to advance treatments for conditions like SARS-CoV-2 (COVID-19), flu, chronic rhinosinusitis (CRS), COPD, and CRBSI.[1] The founding team comprises respected academic researchers and specialized physicians, positioning them to validate the safety and efficacy of their product pipeline, several of which were in development stages early on.[1] Key early support came from NIH grants, enabling proof-of-concept work on NO's broad therapeutic roles in immunity, neural protection, and more.[1][4]
NOTA Laboratories rides the wave of gasotransmitter therapeutics and precision medicine, capitalizing on NO's established roles in innate immunity, neuroprotection, and vasodilation amid rising demand for non-antibiotic antimicrobials and anti-inflammatory treatments.[1][4] Timing aligns with post-COVID emphasis on respiratory antivirals and infection prevention, plus growing needs in neonatal care, cardiology, and home-based chronic disease management, fueled by antimicrobial resistance and aging populations.[1][2] By developing platform tech applicable across conditions like COPD and CRBSI, NOTA influences healthcare ecosystems through affordable innovations that reduce hospital stays and clotting risks, potentially lowering costs in high-burden areas like surgery and ICU care.[3][4]
NOTA's pipeline positions it for expansion into clinical trials and commercialization of NOGEN/LANOR systems, with next steps likely involving FDA approvals for PPHN, surgical, and at-home uses amid trends in personalized NO therapies and AI-optimized delivery.[1][4] Evolving regulatory support for NO in antivirals/thrombosis prevention, plus biotech funding recovery, could amplify growth; influence may grow via partnerships in medtech, shaping antimicrobial alternatives in a post-antibiotic era. This builds on their core mission of harnessing NO to combat life-threatening diseases.[1]
